Wall Street Zen upgraded shares of NervGen Pharma (NASDAQ:NGEN – Free Report) from a sell rating to a hold rating in a research report report published on Friday.
A number of other analysts have also recently weighed in on the stock. Weiss Ratings initiated coverage on shares of NervGen Pharma in a report on Friday, April 24th. They set a “sell (d-)” rating on the stock. HC Wainwright upgraded shares of NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. Zacks Research upgraded shares of NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th. Finally, Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a research report on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.
Check Out Our Latest Research Report on NervGen Pharma
NervGen Pharma Price Performance
NervGen Pharma (NASDAQ:NGEN – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported $999.00 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $999.07.
NervGen Pharma Company Profile
NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.
The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.
Featured Stories
- Five stocks we like better than NervGen Pharma
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
